Is Core Laboratories, Inc. overvalued or undervalued?

As of 7 July 2025, the valuation grade for Core Laboratories, Inc. has moved from expensive to very expensive, indicating a significant concern regarding its valuation. The company appears overvalued based on its current metrics, with a P/E ratio of 21, a Price to Book Value of 2.08, and an EV to EBITDA of 10.54. Comparatively, its peer, which has a P/E of 22.72 and an EV to EBITDA of 11.61, suggests that Core Laboratories is trading at a premium despite its higher valuation grade.
The company's recent performance has also been lackluster, with a year-to-date return of -26.75%, significantly underperforming the S&P 500's return of 12.22% during the same period. This trend continues over longer horizons, with a 5-year return of -29.32% compared to the S&P 500's 96.61%, further reinforcing the notion that Core Laboratories is overvalued in its current state.